Received Apr 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 1 | — | OT |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 2 | — | OT |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 3 | — | OT |
non-responder; This literature marketed report has been received from the authors of a published literature article concerning a patient of unknown age and gender with human immunodeficiency virus infection. Concomitant medications included cabotegravir;rilpivirine. On an unknown dates, the patient was vaccinated with 3 doses of Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) at 0, 1 or 2, and 6 months administered intramuscularly for prophylaxis (dose, vaccination site, lot number and expiration date were not reported). On an unknown date, the patient's hepatitis B antibody surface was negative, it was considered that patient was a non-responder (vaccination failure). Subsequently, the patient was re-vaccinated. The outcome of the event was not provided. Per internal guidelines the event was determined to be related to Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB). This case was classified as non-valid due to the lack of patient's identifiers. Lot # is being requested and will be submitted if received.
HIV infection
Cabotegravir/rilpivirine
Test Name: hepatitis B surface antibody; Test Result: Negative